Atossa Therapeutics Inc

CEO Steven Quay’s recent zero‑cost RSU purchase fuels optimism about Atossa Therapeutics’ upside potential, despite a volatile stock and low liquidity.

Atossa Therapeutics’ CEO buys 325k shares and 950k options, boosting insider confidence despite a 52‑week low, signaling potential upside as the company aims for a clinical breakthrough.